Sign In
Buy IMAB
$4.63
+0 (+0%)
At Close: Apr 14, 2026
I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021
06:00pm, Wednesday, 19'th May 2021
Uliledlimab is a highly differentiated CD73 antibody with a unique epitope that confers pharmacological advantages Data from U.S. phase 1 dose escalation trial demonstrates favorable safety and tolera
The phase 2 combination trial could potentially lead to a registrational study in China in 2022 Accelerated development plan for lemzoparlimab aiming for NDA approval in China for treatment of hematol
I-Mab Added to MSCI China Index
08:00am, Thursday, 13'th May 2021
SHANGHAI and GAITHERSBURG, Md., May 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializat
7 of the Best Pharma Stocks to Buy Now
10:37am, Tuesday, 11'th May 2021
As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first o
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal
05:29pm, Monday, 03'rd May 2021
CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates. Guangzhou Link Health Pharma and Australia's George Clinical plan to form a China clinical CRO JV that will co
I-Mab Announces Upcoming Participation at May Conferences
08:00am, Thursday, 29'th Apr 2021
SHANGHAI and GAITHERSBURG, Md., April 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercial
I-Mab's IL-6 Drug Hits Primary Endpoint Goal In Mid-Stage Ulcerative Colitis Study
09:58am, Monday, 26'th Apr 2021
I-Mab (NASDAQ: IMAB) has announced topline results from its Phase 2 study evaluating olamkicept (also known as TJ301) in patients with active ulcerative colitis (UC). The study met its primary e
I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis
07:00am, Monday, 26'th Apr 2021
SHANGHAI and GAITHERSBURG, Md., April 26, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercializ
SHANGHAI, China., and GAITHERSBURG, MD, April 14, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development
I-Mab Announces Upcoming Participation at April Conferences
08:00am, Wednesday, 31'st Mar 2021
SHANGHAI, China and GAITHERSBURG, Md., March 31, 2021 (GLOBE NEWSWIRE) -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and c
SHANGHAI, China and GAITHERSBURG, Md., March 30, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the development of novel bio
I-Mab to Host 2021 R&D Day
08:00am, Wednesday, 24'th Mar 2021
Mandarin session on April 7, 2021 and English session on April 26, 2021 for investors and research analysts
I-Mab Files Prospectus Supplement for Shelf Registration for Hillhouse
04:20pm, Friday, 19'th Mar 2021
SHANGHAI, China and GAITHERSBURG, Md., March 19, 2021 (GLOBE NEWSWIRE) -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and c
I-Mab Poised To Capitalize On Growing Oncology Sector, Needham Says In Bullish Initiation
10:53am, Monday, 15'th Mar 2021
Shares of the U.S.-listed Chinese immuno-oncology company I-Mab (NASDAQ: IMAB) offer strong upside potential, according to a Needham analyst. The I-Mab Analyst: Chad Messer initiated coverage of I-M
I-MAB BioPharma And Its Dual Drug Portfolio
10:21am, Wednesday, 10'th Mar 2021
I-MAB BioPharma is a new player in the global pharmaceuticals market with autoimmune products.
